Escitalopram for the treatment of major depression and anxiety disorders

References

• Burke WJ, Kratochvil CJ. Stereoisomers in psychiatry: the case of escitalopram. Primary care companion. J. Clin. Psychiatry4, 20–24 (2002).
   Google Scholar
• Sanchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology174, 163–176 (2004).
   PubMed Web of Science ®Google Scholar
• Hyttel J, Bøgesø KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the S-(+)-enantiomer. J. Neural. Transm. Gen. Sect.88, 157–160 (1992).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry50, 345–350 (2001).
   PubMed Web of Science ®Google Scholar
• Mørk A, Kreilgaard M, Sanchez C, Brennum L, Wiborg O. In vitro and in vivo effects of citalopram and its enantiomers on the serotonin uptake transporter. Eur. Neuropsychopharmacol.12(Suppl. 3), 224 (2002) (Abstract 224).
   Google Scholar
• Fabre V, Hamon M. Mechanisms of action of antidepressants: new data from escitalopram. Encephale29, 259–265 (2003).
   PubMedGoogle Scholar
• Mørk A, Kreilgaard M, Sánchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology45(2), 167–173 (2003).
   PubMed Web of Science ®Google Scholar
• Jacquot C, David DJ, Gardier AM, Sánchez C. Escitalopram and citalopram: the unexpected role of the R-enantiomer. Encephale33(2), 179–187 (2007).
   PubMedGoogle Scholar
• Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of citalopram increases inhibitor bindin the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol.15, 193–198 (2005).
   PubMed Web of Science ®Google Scholar
• Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Pharmacology & Toxicology99, 91–95 (2006).
   Google Scholar
• Klein N, Sacher J, Geiss-Granadia T et al.In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology188, 263–272 (2006).
   PubMed Web of Science ®Google Scholar
• Klein N, Sacher J, Geiss-Granadia T et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology191, 333–339 (2007).
   PubMed Web of Science ®Google Scholar
• Sogaard B, Mengel H, Rao N, Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J. Clin. Pharmacol.45, 1400–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jorgenssen T, Sidhu J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insuficiency or hepatic cirrhosis compared with healthy subjects. Eur. J. Clin. Pharmacol.54, 237–242 (1998).
   PubMed Web of Science ®Google Scholar
• Tanum L, Strand LP, Refsum H. S- and R-citalopram ratio in patients treated with racemic citalopram on different dose-levels. Nord J. Psych.57(2), 109 (2003).
   Google Scholar
• Rao N. The clinical pharmacokinetics of escitalopram. Clin. Pharmacokinet.46(4), 281–290 (2007).
   PubMed Web of Science ®Google Scholar
• Moltke von LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug. Metabol. Disp.29, 1102–1109 (2001).
   PubMedGoogle Scholar
• Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol.9(Suppl.1), 19–26 (1994).
   PubMed Web of Science ®Google Scholar
• Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem. Pharmacol.56, 15–23 (1998).
   PubMed Web of Science ®Google Scholar
• Dalgaard L, Larsen C. Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. Xenobiotica29, 1033–1041 (1999).
   PubMed Web of Science ®Google Scholar
• Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br. J. Clin. Pharmacol.60(3), 287–290 (2005).
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Hesse LM, Giancarlo GM, Harmatz SS, Shader RI. The S-enantiomer of citalopram: cytochromes P450 mediating metabolism and cytochrome inhibitory effects. Biol. Psychiatry.49(Suppl.), 48 (2001) (Abstract).
   Google Scholar
• Baumann P, Larsen C. The pharmacokinetics of citalopram. Rev. Contemp. Pharmacotherapy6, 287–295 (1995).
   Google Scholar
• Areberg J, Christophersen JS, Poulsen MN, Larsen F. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J.8, E14–E19 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol. Toxicol.88, 282–286 (2001).
   PubMedGoogle Scholar
• Sanchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav. Pharmacol.14, 465–470 (2003).
   PubMed Web of Science ®Google Scholar
• Mitchell PJ. Antidepressant treatment and rodent aggressive behavior. Eur. J. Pharmacol.526, 147–162 (2005).
   PubMedGoogle Scholar
• Hogg S, Michan L, Jessa M. Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. Neuropharmacology51, 141–145 (2006).
   PubMedGoogle Scholar
• Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality9, 686–692 (1997).
   PubMed Web of Science ®Google Scholar
• Overo KF. Kinetics of citalopram in man; plasma levels in patients. Prog. Neuro-Pharmacol. Biol. Psychiatry6, 311–318 (1982).
   PubMed Web of Science ®Google Scholar
• Mnie-Filali O, Faure C, Mansari ME et al. R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport18(15), 1553–1556 (2007).
   PubMedGoogle Scholar
• Cipralex/Lexapro product monograph. H. Lundbeck A/S, Copenhagen, Denmark 2002 update (2006).
   Google Scholar
• Wade O, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.17, 95–102 (2002).
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol.18(4), 211–217 (2003).
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the simple isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry63, 331–336 (2002).
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology29(Suppl.), S87 (2004).
   Google Scholar
• Ninan PT, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression. Presented at: The Congress of the American Psychiatric Association. San Francisco, CA, USA 17–22 May, 2003 (Poster).
   Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J. Clin. Psychiatry65, 44–49 (2004).
   PubMed Web of Science ®Google Scholar
• Wade A, Despiegel N, Heldbo RE. Escitalopram in the long-term treatment of major depressive disorder. Ann. Clin. Psychiatry18(2), 83–89 (2006).
   PubMedGoogle Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr.7(Suppl. 1), 40–44 (2002).
   PubMed Web of Science ®Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int. Clin. Psychopharmacol.19(3), 149–155 (2004).
   PubMed Web of Science ®Google Scholar
• Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int. J. Psych. Clin. Pract.7, 259–268 (2003).
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry39(5), 180–184 (2006).
   PubMed Web of Science ®Google Scholar
• Fantino B, Moore N, Verdoux H, Auray JP. Cost–effectiveness of escitalopram vs. citalopram in major depressive disorder. Int. Clin. Psychopharmacol.22(2), 107–115 (2007).
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol.20(3),131–137 (2005).
   PubMed Web of Science ®Google Scholar
• Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. J. Clin. Therapeut.29, 2319–2332 (2007).
   PubMed Web of Science ®Google Scholar
• Lancon C, Sapin C, Note I, Farisse J. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. Int. J. Psych. Clin. Prac.10, 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin.22(7), 1331–1341 (2006).
   PubMed Web of Science ®Google Scholar
• Ventura D, Armstrong EP, Skrepnek GH, Haim EM. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr. Med. Res. Opin.23(2), 245–250 (2007).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology50, 57–64 (2004).
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder. J. Clin. Psychiatry65, 1190–1196 (2004).
   PubMed Web of Science ®Google Scholar
• Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost–effectiveness vs venlafaxine extended-release formulation. Int. J. Clin. Pract.61(4), 702–710 (2007).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder comapred with conventional selective serotonin reuptake inhibitors and venlafaxine XR. A meta-analysis. J. Psychiatry Neurosci.31, 122–131 (2006).
   PubMed Web of Science ®Google Scholar
• Eckert L, Falissard B. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR. Curr. Med. Res. Opin.22(11), 2313–2321 (2006).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry67(5), 736–746 (2006).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Montgomery SA, Thase ME, Katz JR, Krishen A, Tucker VL. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. J. Clin. Psychiatry68, 1907–1912 (2007).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Greist JH, Mallinckrodt CH et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin.23(2), 401–416 (2007).
   PubMed Web of Science ®Google Scholar
• Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr. Med. Res. Opin.27, 1303–1318 (2007).
   Google Scholar
• Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin. Drug Invest.7, 481–492 (2007).
   Google Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin.23(7), 1605–1614 (2007).
   PubMed Web of Science ®Google Scholar
• Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry39, 128–134 (2006).
   PubMed Web of Science ®Google Scholar
• Lydiard B. Escitalopram effects on anxiety symptoms in MDD. World J. Biol. Psychiatry.2(Suppl.) (2001) (Abstract 337).
   Google Scholar
• Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress. Anxiety24(1), 53–61 (2007).
   PubMed Web of Science ®Google Scholar
• Olié JP, Tonnoir B, Ménard F, Galinowski A. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress. Anxiety24(5), 318–324 (2007).
   PubMedGoogle Scholar
• Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am. J. Geriatr. Psychiatry.15(7), 581–593 (2007).
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J. Clin. Psychiatry67, 1767–1775 (2006).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry64(11), 1322–1327 (2003).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry40(4), 152–156 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety19(4), 234–240 (2004).
   PubMed Web of Science ®Google Scholar
• Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomized, placebo-controlled, flexible-dosage study. Br. J. Psychiatry186, 222–226 (2005).
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord.87, 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann. Clin. Psychiatry17, 71–75 (2005).
   PubMedGoogle Scholar
• Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J. Clin. Psychopharmacol.26(1), 67–70 (2006).
   PubMedGoogle Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry17(2), 65–69 (2005).
   PubMedGoogle Scholar
• Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol.9(5), 495–505 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry66(11), 1441–1446 (2005).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Trap Huusom AK, Maehlem E. Escitalopram and paroxetine in the treatment of generalized anxiety disorder. Randomized, placebo-controlled, double-blind study. Br. J. Psychiatry189, 264–272 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry66(10), 1270–1278 (2005), Comment in: Evid. Based. Ment. Health9(2), 52 (2006).
   PubMed Web of Science ®Google Scholar
• Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomized, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety19(4), 241–248 (2004).
   PubMed Web of Science ®Google Scholar
• Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J. Psychopharmacol.21(1), 102–111 (2007).
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin.23(4), 701–711 (2007).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Lemming O, Tonnoir B, Stein DJ. Escitalopram prevents relapse of obsessive–compulsive disorder. Eur. Neuropsychopharmacol.17, 430–439 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenthal M, Zornberg G, Li D. Efficacy and tolerability of escitalopram in patients intolerant of other SSRIs. Int. J. Neuropsychopharmacol.5(Suppl. 1), S147 (2002) (Abstract P.3.E.038).
   PubMedGoogle Scholar
• Baldwin DS, Reines EH, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Annals Pharmacother.41, 1583–1592 (2007).
   PubMed Web of Science ®Google Scholar
• Gergel I, Hakkarainen H, Zornberg G. Escitalopram is a well tolerated SSRI. Presented at: The 155th Annual Meeting of the American Psychiatric Association. PA, USA, 18–23 May, 2002 (Abstract 91).
   Google Scholar
• Lexapro (escitalopram oxalate) approved labeling. Forest Pharmaceuticals, Inc., St. Louis, NY, USA (2007).
   Google Scholar
• Lane RM. SSRIs and hyponatremia. Br. J. Clin. Pract.51, 144–146 (1997).
   PubMedGoogle Scholar
• Nelva A, Guy C, Tardy-Poncet B et al. Hemorhagic symptoms related to selective serotonin reuptake inhibitor (SSRI) antidepressants: seven case reports and review of the literature. Rev. Med. Interne.21, 152–160 (2000).
   PubMedGoogle Scholar
• Pedersen AG. Escitalopram and suicidality in adult depression and anxiety. Int. Clin. Psychopharmacol.20, 139–143 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkinson C, Lee GS, Chang C-C, Ventura D. The effects of escitalopram administered alone and with alcohol on cognition and psychomotor performance. Biol. Psychiatry53, S145 (2003).
   Google Scholar
• Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur. Neuropsychopharmacol.11, 275–283 (2001).
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Abramowitz W. Lack of pharmacokinetic interaction between escitalopram and the CYP3A4 inhibitor ritonavir. Biol. Psychiatry49, 51 (2001) (Abstract).
   Google Scholar
• Lo Vecchio F, Watts D, Winchell J, Knight J, McDowell T. Outcomes after supratherapeutic escitalopram ingestions. J. Emerg. Med.30(1), 17–19 (2006).
   PubMed Web of Science ®Google Scholar
• Yuksel FV, Tuzer V, Goka E. Escitalopram intoxication. Eur. Psychiatry20(1), 82 (2005).
   PubMed Web of Science ®Google Scholar
• Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs65(16), 2379–2404 (2005).
   PubMed Web of Science ®Google Scholar
• Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs20(9), 763–790 (2006).
   PubMed Web of Science ®Google Scholar
• Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin. Pharmacother.7(4), 429–440 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics23(2), 155–167 (2005).
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin. Ther.27, 486–496 (2005).
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost–effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr. Med. Res. Opin.21, 631–664 (2005).
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost–effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin. Ther.27, 111–124 (2005).
   PubMed Web of Science ®Google Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost–effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr. Med. Res. Opin.20, 869–878 (2004).
   PubMed Web of Science ®Google Scholar
• Jorgensen TR, Stein DJ, Despiegel N, Drost PB, Hemels ME, Baldwin DS. Cost–effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann. Pharmacother.40, 1752–1758 (2006).
   PubMed Web of Science ®Google Scholar
• Kulp W, von der Schulenburg JM, Greiner W. Cost–effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur. J. Health Econ.6, 317–321 (2005).
   PubMedGoogle Scholar
• Löthgren M, Hemels M, François C, Jönsson B. A cost–effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Prim. Care Psychiatry9, 153–161 (2004).
   Web of Science ®Google Scholar
• Sorensen J, Stage KB, Damsbo N, Lay AL, Hemels ME. A Danish cost–effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord. J. Psychiatry.61, 100–108 (2007).
   PubMed Web of Science ®Google Scholar
• Lancon C, Verpillat P, Annemans L, Despiegel N, Francois C. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int. J. Psychiatry Clin. Pract.11, 44–52 (2007).
   PubMed Web of Science ®Google Scholar
• François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost–effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J. Med. Econ.5, 91–107 (2002).
   Google Scholar
• Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder. Presented at: The 155th Annual Meeting of the American Psychiatric Association. PA, USA, 18–23 May, 2002 (Abstract 131).
   Google Scholar
• Kasper S, Loft H, Smith JR. Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. Presented at: The 155th Annual Meeting of the American Psychiatric Association. PA, USA, 18–23 May, 2002 (Abstract 133).
   Google Scholar
• von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug. Metab. Dispos.29(8), 1102–1109 (2001).
   PubMed Web of Science ®Google Scholar